Safety and efficacy of azacitidine in myelodysplastic syndromes
Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAPurpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed.Summary: Azacitidine is the first drug...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-09-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | http://www.dovepress.com/safety-and-efficacy-of-azacitidine-in-myelodysplastic-syndromes-a5251 |
| _version_ | 1819200391586250752 |
|---|---|
| author | Carlos E Vigil Taida Martin-Santos Guillermo Garcia-Manero |
| author_facet | Carlos E Vigil Taida Martin-Santos Guillermo Garcia-Manero |
| author_sort | Carlos E Vigil |
| collection | DOAJ |
| description | Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAPurpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed.Summary: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m2 daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed.Conclusion: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.Keywords: Azacitidine, MDS, hypomethylating agents |
| first_indexed | 2024-12-23T03:31:29Z |
| format | Article |
| id | doaj.art-33dfcc6ba6bd43289c410863a11e3c55 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-23T03:31:29Z |
| publishDate | 2010-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-33dfcc6ba6bd43289c410863a11e3c552022-12-21T18:01:39ZengDove Medical PressDrug Design, Development and Therapy1177-88812010-09-012010default221229Safety and efficacy of azacitidine in myelodysplastic syndromesCarlos E VigilTaida Martin-SantosGuillermo Garcia-ManeroCarlos E Vigil, Taida Martin-Santos, Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAPurpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed.Summary: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m2 daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed.Conclusion: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.Keywords: Azacitidine, MDS, hypomethylating agentshttp://www.dovepress.com/safety-and-efficacy-of-azacitidine-in-myelodysplastic-syndromes-a5251 |
| spellingShingle | Carlos E Vigil Taida Martin-Santos Guillermo Garcia-Manero Safety and efficacy of azacitidine in myelodysplastic syndromes Drug Design, Development and Therapy |
| title | Safety and efficacy of azacitidine in myelodysplastic syndromes |
| title_full | Safety and efficacy of azacitidine in myelodysplastic syndromes |
| title_fullStr | Safety and efficacy of azacitidine in myelodysplastic syndromes |
| title_full_unstemmed | Safety and efficacy of azacitidine in myelodysplastic syndromes |
| title_short | Safety and efficacy of azacitidine in myelodysplastic syndromes |
| title_sort | safety and efficacy of azacitidine in myelodysplastic syndromes |
| url | http://www.dovepress.com/safety-and-efficacy-of-azacitidine-in-myelodysplastic-syndromes-a5251 |
| work_keys_str_mv | AT carlosevigil safetyandefficacyofazacitidineinmyelodysplasticsyndromes AT taidamartinsantos safetyandefficacyofazacitidineinmyelodysplasticsyndromes AT guillermogarciamanero safetyandefficacyofazacitidineinmyelodysplasticsyndromes |